Reprogramação da diferenciação na metaplasia intestinal e displasia gástrica: um papel para SOX2 e CDX2

send to a friend share this

Reprogramação da diferenciação na metaplasia intestinal e displasia gástrica: um papel para SOX2 e CDX2

Tuesday, 23.09.2014

Neste trabalho caracterizámos o padrão de expressão de dois fatores de transcrição, SOX2 e CDX2 na metaplasia intestinal (MI) e displasia gástricas, duas lesões que precedem o desenvolvimento do cancro gástrico. Os nossos resultados providenciam uma base molecular para perceber a heterogeneidade das lesões metaplásicas e favorecem a hipótese de que a displasia surge a partir da MI. Estes resultados têm implicações clinicas uma vez que aconselham uma vigilância mais apertada de pacientes com MI.

 

Autores e afiliações:

Vânia Camilo1, Mónica Garrido2, Pedro Valente2, Sara Ricardo1, Ana Luísa Amaral1, Rita Barros1, Paula Chaves3, Fátima Carneiro1,2,4, Leonor David1,2, Raquel Almeida1,2,5

 1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

2Faculty of Medicine of the University of Porto, Porto, Portugal

3Portuguese Oncology Institute Francisco Gentil, E.P.E., Lisbon, Portugal

4Pathology Department, Centro Hospitalar S. João, Porto, Portugal

5Biology Department, Faculty of Sciences of the University of Porto, Porto, Portugal

 

Abstract:

Aims: Intestinal metaplasia (IM), which results from de novo expression of CDX2, and dysplasia are precursor lesions of gastric cancer associated with increased risk for cancer development. Multiple evidence suggest a role for SOX2 transcription factor in gastric differentiation. In an attempt to establish SOX2 relationship with CDX2 and with the differentiation reprogramming that characterizes gastric carcinogenesis, we assessed their involvement in IM and dysplasia.

Methods and Results: Characterization of gastric (SOX2, MUC5AC, MUC6) and intestinal (CDX2 and MUC2) markers in normal gastric mucosa, in 55 foci of IM and in 26 foci of dysplasia, was performed by immunohistochemistry. SOX2 was expressed in the normal gastric mucosa, in the presumptive stem cell compartment, and was maintained in 7% of the complete (MUC5AC-) and 85% of the incomplete (MUC5AC+) IM subtypes. 12% of the dysplastic lesions expressed SOX2 and the association with MUC5AC was lost. CDX2 was present in all IM and dysplastic lesions.

Conclusions: SOX2 associates with gastric differentiation in incomplete IM and is lost in the progression to dysplasia, whereas CDX2 is de novo acquired in IM and maintained in dysplasia. This suggests that the balance between gastric and intestinal differentiation programs impacts on the gastric carcinogenesis cascade progression.

 

Revista:  Histopathology

 

Link: http://onlinelibrary.wiley.com/doi/10.1111/his.12544/abstract;jsessionid=A69C9483F299B5BA5F00A41A814936FD.f04t02